Compare GNL & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNL | DRTS |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2011 | 2021 |
| Metric | GNL | DRTS |
|---|---|---|
| Price | $6.89 | $13.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $9.88 | ★ $17.80 |
| AVG Volume (30 Days) | ★ 3.1M | 472.4K |
| Earning Date | 11-04-2026 | 11-19-2026 |
| Dividend Yield | ★ 10.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $495,286,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.83 | $1,235.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.81 | $3.43 |
| 52 Week High | $10.04 | $15.79 |
| Indicator | GNL | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 29.23 | 51.90 |
| Support Level | N/A | $13.73 |
| Resistance Level | $9.48 | $13.95 |
| Average True Range (ATR) | 0.23 | 0.67 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 12.06 | 76.47 |
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operation, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution, Retail, and Office. The company derives maximum revenue from the Industrial and Distribution segment. The company geographically operates in the United States, the United Kingdom, Canada, and Europe.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.